Table 4.

Overall Survival; Cox Regression Analysis

	POSIBA				PULSE
	Univariate		Multivariate		Univariate		Multivariate
	HR (95% CI)	P Value	HR (95% CI)	P Value	HR (95% CI)	P Value	HR (95% CI)	P Value
DP	1.73 (1.06-2.85)	.029	1.67 (0.96-2.90)	.070	0.54 (0.29-0.99)	.048	0.23 (0.11-0.52)	.0004
ECOG-PS >0	2.95 (2.03-4.29)	<.0001	2.48 (1.63-3.77)	<.0001	2.20 (1.18-4.08)	.013	2.93 (1.30-6.62)	.0097
Age >65 years	1.24 (0.85-1.79)	.26	1.00 (0.65-1.53)	.99	1.37 (0.74-2.53)	.32	1.48 (0.64-3.47)	.36
BRAF mutated	3.38 (2.00-5.72)	<.0001	2.32 (1.23-4.36)	.0092	4.23 (1.17-10.48)	.0018	10.3 (1.08-58.3)	.0086
Surgery of primary tumor	1.60 (1.10-2.32)	.013	1.36 (0.90-2.07)	.15	0.35 (0.19-0.66)	.0010	0.20 (0.08-0.48)	.0003
Left-sided primary tumor	1.06 (0.73-1.53)	.78	0.82 (0.51-1.31)	.40	0.60 (0.28-1.31)	.20	0.47 (0.15-1.48)	.20
CEA (logarithmic term)	0.42 (0.28-0.62)	<.0001	0.47 (0.30-0.74)	.0012	1.09 (0.94-1.25)	.25	0.91 (0.75-1.10)	.32
LDH (logarithmic term)	0.99 (0.91-1.08)	.80	1.00 (0.89-1.12)	.97	1.30 (0.85-2.01)	.23	1.40 (0.79-2.43)	.25
Liver metastasis	0.95 (0.72-1.26)	.73	0.92 (0.66-1.27)	.61
0	Ref.				Ref.
<=3, <=5 cm	0.68 (0.39-1.21)	.19	1.08 (0.57-2.06)	.81	1.72 (0.54-5.46)	.35	2.49 (0.56-11.09)	.23
>3 or >5 cm	0.70 (0.45-1.10)	.12	0.95 (0.51-1.79)	.88	1.73 (0.75-3.95)	.20	1.64 (0.49-5.50)	.42

CEA, carcinoembryonic antigen; CI, confidence interval; DP, double positivity; ECOG-PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio; LDH, lactate dehydrogenase; WT, wild-type.